^
Association details:
| Biomarker: | IL6 elevation + HGF elevation + CCL8 elevation |
|---|---|
| Cancer: | Melanoma |
| Drug Class: | Immunotherapy |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Circulating inflammatory proteins associate with response to immune checkpoint inhibition therapy in patients with advanced melanoma
Published date:
08/22/2022
Excerpt:
We observed consistently higher pre-treatment levels of interleukin-6 (IL-6), hepatocyte growth factor (HGF), and monocyte chemotactic protein 2 (MCP-2), in non-responders compared to responders (meta-analysis p=3.31 × 10-4, 2.29 × 10-4, and 1.02 × 10-3, respectively)....with overall response rate among patients presenting with combined elevated IL-6, HGF, and MCP-2 levels being three-fold lower (26.7%) compared to patients with none of the three proteins elevated (80.0%, p=9.22 × 10-3).
DOI:
10.1016/j.ebiom.2022.104235
